Home › Companies › Aldeyra Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Aldeyra Therapeutics, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 9, 2026: 3 items on Aldeyra Therapeutics, Inc.’s Form 8-K, filed June 10, 2026: 1 elected · 2 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Aldeyra Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Aldeyra Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Todd C. Brady, M.D., Ph.D. | 23,026,101 | -- | -- | 1,081,762 | 20,038,067 | 96% | Elected | — |
| 2. Ratification of Appointment of BDO USA, P.C | 43,693,772 | 321,501 | 130,657 | -- | -- | 99.3% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 19,477,504 | 4,543,221 | 87,138 | -- | 20,038,067 | 81% | Approved | — |
Source: Aldeyra Therapeutics, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
125 asset managers disclosed a vote on at least one Aldeyra Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of one Class III Director: Todd C. Brady, M.D., Ph.D.
Aldeyra Therapeutics, Inc.’s own tally for this item (“Elect Director: Todd C. Brady, M.D., Ph.D.”): 23,026,101 for, 1,081,762 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following director to serve as a Class III director until the 2029 annual meeting of stockholders or until his successor is duly elected and qualified or until earlier death, resignation or removal.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 40 asset managers below reported 5,982,074 for, 178,560 withheld, 5 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,251,013 | 0 | 5 | 4,397 | For |
| BlackRock | 940,905 | 0 | 0 | 0 | For |
| Fidelity | 915,583 | 0 | 0 | 0 | For |
| Charles Schwab | 139,026 | 0 | 0 | 0 | For |
| Equitable | 131,665 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 120,844 | Withhold |
| Goldman Sachs | 104,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 82,124 | 0 | 0 | 0 | For |
| Lincoln Financial | 36,000 | 0 | 0 | 10,494 | Mixed |
| T. Rowe Price | 41,852 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 40,205 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 37,120 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,818 | 0 | 0 | 0 | For |
| Global X | 26,067 | 0 | 0 | 0 | For |
| Russell Investments | 25,961 | 0 | 0 | 0 | For |
| Pacific Life | 21,814 | 0 | 0 | 0 | For |
| TIAA | 21,266 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 21,117 | Withhold |
| CLEARWATER INVESTMENT TRUST | 16,989 | 0 | 0 | 0 | For |
| Northern Trust | 16,597 | 0 | 0 | 0 | For |
| John Hancock | 16,322 | 0 | 0 | 0 | For |
| Nationwide | 15,849 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 14,342 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 0 | 0 | 9,920 | Withhold |
| Voya | 9,448 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. All 40 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
81% Approved · of votes cast
Prior year: 70.4% for (June 10, 2025 meeting) ▲ 10.7 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of Aldeyra Therapeutics, Inc.'s named executive officers.
Aldeyra Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 19,477,504 for, 4,543,221 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,253,250 | 2,165 | 0 | 0 | For |
| BlackRock | 940,905 | 0 | 0 | 0 | For |
| Fidelity | 915,583 | 0 | 0 | 0 | For |
| Charles Schwab | 139,026 | 0 | 0 | 0 | For |
| Equitable | 131,665 | 0 | 0 | 0 | For |
| Dimensional | 0 | 120,844 | 0 | 0 | Against |
| Goldman Sachs | 104,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 82,124 | 0 | 0 | 0 | For |
| Lincoln Financial | 36,000 | 10,494 | 0 | 0 | Mixed |
| T. Rowe Price | 41,852 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 40,205 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 37,120 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,818 | 0 | 0 | 0 | For |
| Global X | 0 | 26,067 | 0 | 0 | Against |
| Russell Investments | 0 | 25,961 | 0 | 0 | Against |
| Pacific Life | 21,814 | 0 | 0 | 0 | For |
| TIAA | 21,266 | 0 | 0 | 0 | For |
| Jackson National | 0 | 21,117 | 0 | 0 | Against |
| CLEARWATER INVESTMENT TRUST | 16,989 | 0 | 0 | 0 | For |
| Northern Trust | 16,597 | 0 | 0 | 0 | For |
| John Hancock | 16,322 | 0 | 0 | 0 | For |
| Nationwide | 15,849 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 14,342 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 9,920 | 0 | 0 | Against |
| Voya | 9,448 | 0 | 0 | 0 | For |
Fund voting reports, all 40 managers: 5,919,060 for, 241,579 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AQR | 1,975,176 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 0 | 1,841,541 | 0 | 0 | Against |
| BlackRock | 1,533,596 | 666 | 0 | 0 | For |
| 683 Capital Management, LLC | 1,500,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,090,641 | 0 | 0 | 0 | For |
| DE Shaw | 1,040,003 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 777,895 | 0 | 0 | 0 | For |
| State Street | 742,348 | 552 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 671,330 | 0 | 0 | 0 | For |
| Vanguard | 356,308 | 0 | 0 | 0 | For |
| ARDSLEY ADVISORY PARTNERS LP | 0 | 350,000 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 340,878 | 0 | 0 | Against |
| WOODSTOCK CORP | 0 | 266,756 | 0 | 0 | Against |
| Two Sigma | 240,734 | 0 | 0 | 0 | For |
| Northern Trust | 197,538 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 186,186 | 0 | 0 | 0 | For |
| WELLS FARGO ADVISORS FINANCIAL NETWORK, LLC | 156,311 | 0 | 0 | 0 | For |
| T. Rowe Price | 147,544 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 144,259 | 0 | 0 | Against |
| Charles Schwab | 139,026 | 0 | 0 | 0 | For |
| Dimensional | 0 | 91,541 | 0 | 0 | Against |
| CANADA PENSION PLAN INVESTMENT BOARD | 71,600 | 0 | 0 | 0 | For |
| Renaissance | 70,502 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 69,007 | 0 | 0 | Against |
| STRS OHIO | 68,200 | 0 | 0 | 0 | For |
Institutional-manager reports, all 99 managers: 11,499,515 for, 3,268,564 against, 1,000 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.3% Approved · of votes cast
Description as filed by funds: To ratify the appointment of BDO USA, P.C. as Aldeyra Therapeutics, Inc.'s independent registered public accounting firm for the year ending December 31, 2026.
Aldeyra Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of BDO USA, P.C”): 43,693,772 for, 321,501 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of Appointment of BDO USA, P.C. The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 40 asset managers below reported 6,160,638 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,255,414 | 0 | 0 | 0 | For |
| BlackRock | 940,905 | 0 | 0 | 0 | For |
| Fidelity | 915,583 | 0 | 0 | 0 | For |
| Charles Schwab | 139,026 | 0 | 0 | 0 | For |
| Equitable | 131,665 | 0 | 0 | 0 | For |
| Dimensional | 120,844 | 0 | 0 | 0 | For |
| Goldman Sachs | 104,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 82,124 | 0 | 0 | 0 | For |
| Lincoln Financial | 46,494 | 0 | 0 | 0 | For |
| T. Rowe Price | 41,852 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 40,205 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 37,120 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,818 | 0 | 0 | 0 | For |
| Global X | 26,067 | 0 | 0 | 0 | For |
| Russell Investments | 25,961 | 0 | 0 | 0 | For |
| Pacific Life | 21,814 | 0 | 0 | 0 | For |
| TIAA | 21,266 | 0 | 0 | 0 | For |
| Jackson National | 21,117 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 16,989 | 0 | 0 | 0 | For |
| Northern Trust | 16,597 | 0 | 0 | 0 | For |
| John Hancock | 16,322 | 0 | 0 | 0 | For |
| Nationwide | 15,849 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 14,342 | 0 | 0 | 0 | For |
| Prudential/PGIM | 9,920 | 0 | 0 | 0 | For |
| Voya | 9,448 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. All 40 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,321,068 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.40% |
| 2 | BlackRock | 1.56% |
| 3 | Fidelity | 1.52% |
| 4 | Charles Schwab | 0.23% |
| 5 | Equitable | 0.22% |
| 6 | Dimensional | 0.20% |
| 7 | Goldman Sachs | 0.17% |
| 8 | QUANTITATIVE MASTER SERIES LLC | 0.14% |
| 9 | Lincoln Financial | 0.08% |
| 10 | T. Rowe Price | 0.07% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | AQR | 3.27% |
| 2 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 3.05% |
| 3 | BlackRock | 2.54% |
| 4 | 683 Capital Management, LLC | 2.49% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.81% |
| 6 | DE Shaw | 1.72% |
| 7 | ACADIAN ASSET MANAGEMENT LLC | 1.29% |
| 8 | State Street | 1.23% |
| 9 | JACOBS LEVY EQUITY MANAGEMENT, INC | 1.11% |
| 10 | Vanguard | 0.59% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 3,763,887 | 6.24% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 3,698,682 | 6.13% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 1,403,990 | 2.33% | Form 13F, quarter ended March 31, 2026 |
| State Street | 1,124,710 | 1.86% | Form 13F, quarter ended March 31, 2026 |
| Millennium Management | 995,243 | 1.65% | Form 13F, quarter ended March 31, 2026 |
| Renaissance Technologies | 863,187 | 1.43% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 657,032 | 1.09% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 624,170 | 1.03% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 60,321,068 shares outstanding, as reported by Aldeyra Therapeutics, Inc. on its Form 10-Q dated May 5, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Aldeyra Therapeutics, Inc.'s shareholder meeting held June 9, 2026, in the 2025-2026 proxy season, 125 asset managers reported votes on at least one of its 3 ballot items in their SEC Form N-PX filings, covering 476 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of Aldeyra Therapeutics, Inc.'s… — Aldeyra Therapeutics, Inc.'s filing reports the proposal as approved, with 81% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Aldeyra Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Aldeyra Therapeutics, Inc.’s 10-Q dated May 5, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Aldeyra Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Aldeyra Therapeutics (ALDX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/aldeyra-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.